Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity.
Pharmacogenomics
; : 1-9, 2024 Aug 02.
Article
in En
| MEDLINE
| ID: mdl-39092502
ABSTRACT
Aim:
This study evaluated associations between CYP3A4*22 and variants in other pharmacogenes (CYP3A5, SULT2A1, ABCB1, ABCG2, ERCC1) and the risk for palbociclib-associated toxicities. Materials &methods:
Two hundred cancer patients who received standard-of-care palbociclib were genotyped and associations with toxicity were evaluated retrospectively.Results:
No significant associations were found for CYP3A4*22, CYP3A5*3, ABCB1_rs1045642, ABCG2_rs2231142, ERCC1_rs3212986 and ERCC1_rs11615. Homozygous variant carriers of SULT2A1_rs182420 had higher incidence of dose modifications due to palbociclib toxicity (odds ratio [OR] 4.334, 95% CI 1.057-17.767, p = 0.042). ABCG2_rs2231137 variant carriers had borderline higher incidence of grade 3-4 neutropenia (OR 4.14, 95% CI 0.99-17.37, p = 0.052).Conclusion:
Once validated, SULT2A1 and ABCG2 variants may be useful to individualize palbociclib dosing to minimize toxicities and improve treatment outcomes.
[Box see text].
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Pharmacogenomics
Journal subject:
FARMACOLOGIA
/
GENETICA MEDICA
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom